

## REMARKS

### The Office Action

Claims 83, 87, 88, 90, 101, 102, 112, and 113 were pending in this application. Claims 1-82, 84-86, 89, 91-100, and 103-111 were previously canceled. With this reply claims 90, 101, 102, 112, and 113 are canceled and claims 114-149 have been added. Thus, with this reply claims 83, 87, 88, and 114-123 are pending and under examination. Claim 83 stands rejected under 35 U.S.C. § 112, first paragraph, for reciting new matter. Claim 83 stands further rejected under 35 U.S.C. § 102 for lack of novelty and under 35 U.S.C. § 103 for obviousness. Claims 87, 88, 90, 101, 102, 112, and 113 are objected to for their dependence on a rejected claim.

### Rejection Under 35 U.S.C. § 112, first paragraph

Claims 83 stands rejected under 35 U.S.C. § 112, first paragraph, as containing subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor, at the time the application was filed, had possession of the claimed invention. The Examiner asserts support is lacking for Z comprising one residue selected from Glu, Lys, and Met. Applicants have addressed this rejection by amendment of the claim 83.

With respect to the definition of Z, claim 83 has been amended to remove the term “comprising one residue selected from Glu, Lys, and Met.” As amended, the definition of

Z is limited to specific sequences for which explicit support is found in the specification at page 16, lines 1-30.

In view of this amendment to claim 83, applicants request that the rejection for new matter be withdrawn.

Rejection Under 35 U.S.C. § 102 and § 103

Claim 83 stands rejected under 35 U.S.C. § 102 as anticipated by Li (U.S. Patent No. 4,081,434) and under 35 U.S.C. § 103 as obvious over Li. As a basis for this rejection, the Examiner cites a peptide disclosed at column 4, line 40, of Li which includes a lysine residue at the C terminus. The Examiner further notes that claim 83 encompasses peptide conjugate in which Z comprises one residue selected from Glu, Lys, and Met. Applicants have address both of these rejections together by amendment of claim 83.

With respect to the definition of Z, claim 83 has been amended to remove the term “comprising one residue selected from Glu, Lys, and Met.” As amended, the definition of Z is limited to specific sequences, the conjugates of which do not encompass the peptide described by Li.

In view of this amendment to claim 83, applicants request that the rejection for lack of novelty and obviousness be withdrawn.

Support for the amendment to claim 83 and new claims 114-123

With this reply claim 83 has been amended and new claims 114-123 have been added.

Support for X being selected from eptifibatide, as recited in claim 83, is found in the specification at page 10, line 24 (eptifibatide).

Support for X being selected from gonadotropin releasing hormone, human parathyroid hormone (1-34), growth hormone, oxytocin, glucagon, peptide YY, exendin-4, bivalirudin, and hirulog-1, AF 12505, vasopressin, vasoactive intestinal peptide, vasotocin, growth hormone (GH)-releasing peptide-6 (GHRP-6), exendin-3 (GLP-I analog), LHRH, kyotorphin, C-type natriuretic peptide (1-53), cortistatin 14, EMP-1, Atrial natriuretic peptide, human brain natriuretic peptide, gastric inhibitory polypeptide, glucagon-like peptide-1, glucagon-like peptide-2, pituitary adenylate cyclase activating polypeptide, pancreatic polypeptide, somatostatin, octreotide (201-995), calcitonin, PD-145065, PD-142893, eptifibatide, and Melanotan-II, as recited in claims 114-147, is found in claim 83, and in the specification from pages 8 to 11.

Support for Z is  $(\text{Lys})_n$  in which n is an integer from 4 to 10, as recited in claim 148, is found in the specification at page 15, lines 21-24.

Support for Z is  $\text{Lys}_6$  (SEQ ID NO: 62), as recited in claim 149, is found in the specification at page 15, lines 23-26.

## CONCLUSION

Applicants submit that the claims are now in condition for allowance and such action is respectfully requested. To expedite prosecution applicants request a telephonic interview with the Examiner to discuss any remaining rejections. The Examiner is invited to call the undersigned at 617-428-0200.


Enclosed is a Petition to extend the period for replying to the Office action for three months, to and including Monday October 1, 2007, as September 29, 2007, fell on a Saturday, and a check in payment of the required extension fee.

With this reply new claims have been added resulting in 105 total claims, 1 multiply dependent claim and 1 independent claim. Enclosed is a check for \$4,620 (85x50+\$370) for the 85 extra claims and 1 multiply dependent claim.

If there are any additional charges or any credits, please apply them to Deposit Account No. 03-2095.

Respectfully submitted,

Date: October 1, 2007

  
\_\_\_\_\_  
Kristina Bieker-Brady, Ph.D.  
Reg. No. 39,109

Clark & Elbing LLP  
101 Federal Street  
Boston, MA 02110  
Telephone: 617-428-0200  
Facsimile: 617-428-7045